Epizyme Inc (EPZM) Receives Average Recommendation of “Buy” from Analysts

Epizyme Inc (NASDAQ:EPZM) has been assigned a consensus recommendation of “Buy” from the fifteen analysts that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation and eleven have issued a buy recommendation on the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $23.00.

EPZM has been the subject of a number of recent research reports. Cann reiterated a “buy” rating and set a $26.00 price objective on shares of Epizyme in a research report on Thursday, November 2nd. Royal Bank of Canada cut Epizyme from an “outperform” rating to a “sector perform” rating and dropped their price objective for the stock from $20.00 to $16.00 in a research report on Thursday, November 2nd. Leerink Swann reiterated an “outperform” rating and set a $22.00 price objective (down previously from $28.00) on shares of Epizyme in a research report on Thursday, November 2nd. HC Wainwright reiterated a “buy” rating and set a $25.00 price objective on shares of Epizyme in a research report on Thursday, November 2nd. Finally, ValuEngine cut Epizyme from a “hold” rating to a “sell” rating in a report on Monday, November 6th.

Shares of Epizyme (EPZM) opened at $17.45 on Wednesday. The company has a market capitalization of $1,160.00, a PE ratio of -7.69 and a beta of 2.19. Epizyme has a 52-week low of $9.30 and a 52-week high of $20.45.

In other Epizyme news, COO Matthew Ros sold 72,264 shares of Epizyme stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $16.63, for a total value of $1,201,750.32. Following the completion of the sale, the chief operating officer now owns 74,867 shares in the company, valued at approximately $1,245,038.21. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 25.20% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company lifted its stake in shares of Epizyme by 3.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 33,137 shares of the biopharmaceutical company’s stock valued at $501,000 after purchasing an additional 1,068 shares in the last quarter. California Public Employees Retirement System lifted its stake in shares of Epizyme by 2.2% in the 2nd quarter. California Public Employees Retirement System now owns 135,500 shares of the biopharmaceutical company’s stock valued at $2,046,000 after purchasing an additional 2,900 shares in the last quarter. Teachers Advisors LLC lifted its stake in shares of Epizyme by 5.8% in the 2nd quarter. Teachers Advisors LLC now owns 73,952 shares of the biopharmaceutical company’s stock valued at $1,117,000 after purchasing an additional 4,030 shares in the last quarter. Alps Advisors Inc. lifted its stake in shares of Epizyme by 9.1% in the 3rd quarter. Alps Advisors Inc. now owns 57,472 shares of the biopharmaceutical company’s stock valued at $1,095,000 after purchasing an additional 4,797 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in shares of Epizyme by 2.6% in the 3rd quarter. Bank of New York Mellon Corp now owns 202,178 shares of the biopharmaceutical company’s stock valued at $3,852,000 after purchasing an additional 5,140 shares in the last quarter. 85.99% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Epizyme Inc (EPZM) Receives Average Recommendation of “Buy” from Analysts” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The legal version of this report can be read at https://www.americanbankingnews.com/2018/02/14/epizyme-inc-epzm-receives-average-recommendation-of-buy-from-analysts.html.

About Epizyme

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).

Analyst Recommendations for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply